ColoFuture

About Mainz Biomed

Mainz Biomed is a commercial-stage molecular diagnostics company with a mission to transform cancer screening through convenient, at-home tests. Its core achievement is the CE-marked ColoAlert® test for colorectal cancer (CRC), which is marketed in Europe and is undergoing a pivotal FDA registration trial (ReconAAsense) in the U.S. The company's strategy is to penetrate the massive CRC screening market first, then leverage its platform for a multi-cancer early detection (MCED) pipeline, including pancreatic cancer. Recent corporate actions include a planned name change to Quantum Cyber and a $6.0 million private placement to fund operations.

Therapeutic Areas